Integrating BRAF/MEK inhibitors into combination therapy for melanoma

The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Smalley, K S M, Flaherty, K T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658537/
https://www.ncbi.nlm.nih.gov/pubmed/19156138
http://dx.doi.org/10.1038/sj.bjc.6604891
_version_ 1782165638809124864
author Smalley, K S M
Flaherty, K T
author_facet Smalley, K S M
Flaherty, K T
author_sort Smalley, K S M
collection PubMed
description The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.
format Text
id pubmed-2658537
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26585372010-02-10 Integrating BRAF/MEK inhibitors into combination therapy for melanoma Smalley, K S M Flaherty, K T Br J Cancer Minireview The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing. Nature Publishing Group 2009-02-10 2009-01-20 /pmc/articles/PMC2658537/ /pubmed/19156138 http://dx.doi.org/10.1038/sj.bjc.6604891 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Smalley, K S M
Flaherty, K T
Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title_full Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title_fullStr Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title_full_unstemmed Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title_short Integrating BRAF/MEK inhibitors into combination therapy for melanoma
title_sort integrating braf/mek inhibitors into combination therapy for melanoma
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658537/
https://www.ncbi.nlm.nih.gov/pubmed/19156138
http://dx.doi.org/10.1038/sj.bjc.6604891
work_keys_str_mv AT smalleyksm integratingbrafmekinhibitorsintocombinationtherapyformelanoma
AT flahertykt integratingbrafmekinhibitorsintocombinationtherapyformelanoma

Ejemplares similares